HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AZD8835

antineoplastic; structure in first source

Also Known As:

1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        AZD8835: 7
  - Piperidines: 17
    - AZD8835: 7

Experts

1.	Hudson, Kevin: 3 articles (12/2018 - 11/2015)
2.	Barry, Simon T: 2 articles (12/2018 - 04/2016)
3.	Crafter, Claire: 2 articles (12/2018 - 04/2016)
4.	McEwen, Robert: 2 articles (04/2016 - 01/2016)
5.	Ellston, Rebecca: 2 articles (01/2016 - 11/2015)
6.	Green, Stephen: 2 articles (01/2016 - 11/2015)
7.	Ward, Lara: 2 articles (01/2016 - 11/2015)
8.	Chen, Chien-Chin: 1 article (01/2020)
9.	Chou, Cheng-Yang: 1 article (01/2020)
10.	Huang, Chia-Yen: 1 article (01/2020)

Related Diseases

1.	Neoplasms (Cancer) 12/27/2018 - "Together these data reveal novel mechanisms by which PI3Kα/δ inhibitors interact with the immune system and validate the clinical compound AZD8835 as a novel immunoncology drug, independent of effects on tumor cells. " 12/27/2018 - "Here we examine the differential effects of AZD8835, a dual PI3Kα/δ inhibitor, specifically on the tumor immune microenvironment using syngeneic models. " 01/01/2016 - "Indeed, using IHDS, monotherapy AZD8835 was able to induce tumor xenograft regression. " 01/01/2016 - "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers." 01/01/2020 - "This study highlights the importance of PI3K/Akt in ovarian tumor progression and chemoresistance and the potential application of AZD compounds, especially AZD8835 and AZD5363, as therapeutic agents for the treatment of ovarian cancer."
2.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2020 - "This study highlights the importance of PI3K/Akt in ovarian tumor progression and chemoresistance and the potential application of AZD compounds, especially AZD8835 and AZD5363, as therapeutic agents for the treatment of ovarian cancer." 01/01/2020 - "AZD compounds did not change the mRNA expression of BRCA1/BRCA in ovarian cancer cells, but AZD8835 inhibited BRCA1/BRCA2 mRNA expression and p-ERK protein expression in OVCAR-8 cells with the KRAS mutation. " 01/01/2020 - "AZD8835 and AZD5363 sensitized chemoresistant ovarian cancer cells to cisplatin and paclitaxel treatment. "
3.	Breast Neoplasms (Breast Cancer) 01/01/2019 - "AZD8835, a novel dual phosphoinositide-3-kinase (PI3K) inhibitor, is currently in phase 1 clinical evaluation to treat breast cancer. " 01/01/2016 - "Consistent with this, AZD8835 demonstrated antitumor efficacy in corresponding breast cancer xenograft models when dosed continuously. " 01/01/2016 - "AZD8835 is a potent inhibitor of PI3Kα and PI3Kδ with selectivity versus PI3Kβ, PI3Kγ, and other kinases that preferentially inhibited growth in cells with mutant PIK3CA status, such as in estrogen receptor-positive (ER(+)) breast cancer cell lines BT474, MCF7, and T47D (sub-μmol/L GI50s). "
4.	Alveolar Bone Loss 01/01/2019 - "AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats."
5.	Periodontitis 01/01/2019 - "AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats."

Related Drugs and Biologics

1.	capivasertib
2.	AZD8186
3.	AZD8835
4.	Cathepsin K
5.	Calcitonin Receptors (Calcitonin Receptor)
6.	Paclitaxel (Taxol)
7.	Messenger RNA (mRNA)
8.	Estrogen Receptors
9.	Proteins (Proteins, Gene)
10.	Phosphotransferases (Kinase)